A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui deal.
A key Republican congressman asked the Trump administration to restrict the stream of money into China’s biotech sector, threatening to squelch the dealmaking that’s become …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
China's ascent is forcing U.S. biotech companies and investors to pick a side: Is it an ally or an existential threat?
China is becoming a leader in biotech innovation. That offers hope to rare disease patients and presents a problem to American…
The veteran investor says that the trove of ready-made prospects is making the global biotech ecosystem “more competitive” and…
Behind the scenes, major pharmaceutical companies and Trump-tied billionaires are furiously lobbying in opposite directions over…
A bipartisan group of lawmakers in both chambers is working to limit advanced chip exports to China.
SR One’s Simeon George on how China is rewriting biotech’s venture playbook
